Ashworth Alan 4

What Happened

• Alan Ashworth, a director of CytomX Therapeutics, was granted a derivative award of 59,000 shares on 2026-06-17. The award shows a $0.00 acquisition price (no cash paid) and is reported as a derivative grant (code A). The filing was made on 2026-06-22.

Key Details

• Transaction date: 2026-06-17; Filing date: 2026-06-22 (filed after the usual two-business-day window).
• Shares granted: 59,000 derivative shares; reported acquisition price: $0.00 (total reported value $0).
• Shares owned following the transaction: not specified in the filing.
• Footnote: 100% of the shares subject to the award vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of stockholders, assuming continuous service as a director until vesting.
• Transaction type: Award/Grant (derivative), not an open-market purchase or sale.

Context

• This is a time-vesting director grant (typical for board compensation) rather than a market purchase or sale; it does not by itself signal a buy or sell decision by the insider.
• Because the award is subject to vesting, the shares are not immediately tradable; no immediate cash exercise or sale was reported.